ghp lobal health & pharma Q1 2026 www.ghp-news.com Abbey House Dental: Staffordshire’s Leading Invisalign and Implant Dentist Featuring: Aesculus Clinic: Aesthetics and Holistic Wellness Converge in New Malden
Welcome to the Q1 2026 edition of Global Health & Pharma magazine, providing you with all of the latest news and features across the healthcare and pharmaceutical landscape. Q1 2026 Over the past year, the healthcare and pharmaceutical world has made remarkable progress. We’ve seen major advances in many areas, and we’re proud to present news and success stories throughout this quarter’s issue. After such an innovative and inspiring 2025, it feels as though the momentum is picking up further as 2026 begins to unfold. The global healthcare and pharmaceutical industries show absolutely no signs of slowing down, in fact, it’s developing more rapidly than ever. A major reason behind this continued growth is the increasing role of artificial intelligence in how new medicines are found and created, helping individuals all around the world. AI is now aiding researchers to identify promising drug candidates far more quickly, easing some of the heavy costs that usually come with development, and improving the chances that clinical trials succeed. There’s so much to enjoy throughout our issues, and the Q1 instalment is no different. In this issue, we invite you to meet the award winning companies contributing to this global progress. Their work spans a wide range of specialties and their success is truly testament to their dedication for the advancement of humankind and our health. We hope you enjoy perusing this edition, and find it both informative and motivational. We look forward to updating you with our Q2 issue. Sofi Parry, Senior Editor Website: ghpnews.digital AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.
Contents 4. News - Employee Mental Health Tops the Concerns and Priorities of Employers for 5th Year Running - Cresilon Receives Innovative Technology Contract from Vizient for TRAUMAGEL 6. How Health IT Can Bring Clarity to End-of-Life Medical Decisions 7. How Leadership, Regulation and Trust Will Define AI’s Future in Pharma 8. Intrinseque Health: Best Clinical Development Supply Chain Solutions Partner 2026 9. Abbey House Dental: Staffordshire’s Leading Invisalign and Implant Dentist 10. Suvoda: Pioneering For Patients, For Professionals, For Progress 12. Dr Raquel Skin and Medical Cosmetics: Personalised Treatments at Kent’s Doctor-Led Aesthetics Clinic 13. Dr M.Sha Wellness and Aesthetics Clinic: Regenerative Treatments with Results You Can Trust 14. Aesculus Clinic: Aesthetics and Holistic Wellness Converge in New Malden 15. Lumineux Aesthetics: Treatments that Illuminate from Inside and Out 16. Vera Clinic: Best Hair Transplant Clinic 2026 - Turkey 18. The Danebury Practice: 2025’s Leading Facial Aesthetics Clinic - Hampshire
NEWS shows just how significant the concern is at present and for the future.” In terms of employee health and wellbeing, on what will your organisation be focussing in the coming year? New research from employee benefits experts, Everywhen, reveals that mental health tops the list of employers’ concerns and priorities for 2026. A significant 59% of employers are concerned about the mental health of their employees. Reflecting this level of concern, 49% of employers will be prioritising support for mental health over the next 12 months. With this priority, it is vital that the support put in place is effective. Employee Mental Health Tops the Concerns and Priorities of Employers for 5th Year Running Mental health concerns Mental health is an ongoing issue in the workplace, having topped the list of concerns every year since Everywhen began conducting annual research in 2022. The 2026 results show: Do any of the following concern you in terms of your employees’ health and wellbeing? Mental health priorities In terms of where employers will focus their health and wellbeing support in the coming year, mental health tops the table of priorities by a significant percentage. Indeed, nearly half (49%) of employers say they will focus on mental health this year. The next priority is financial health, with just 27% of employers focusing on it. Debra Clark, head of wellbeing at Everywhen, says: “We carried out comprehensive research to find out employers’ priorities for this year, including asking about a wide range of important issues such as health screening, MSK support and access to virtual GPs. We know that these areas are a concern for employers, so the fact that mental health came so high above these other priorities The building blocks of health and wellbeing Employers will need to be careful not to let mental health overshadow the other areas where employees are in need of support. It is important to remember the interconnection of mental health with the other pillars of wellbeing – physical, social and financial. Therefore, in order to improve the mental health of employees, employers must
Cresilon announced its revolutionary hemostatic gel TRAUMAGEL® has received an Innovative Technology contract from Vizient® the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on review of TRAUMAGEL from hospital experts who serve on one of Vizient’s clientled councils, and it signifies to Vizient clients its unique qualities that potentially bring improvement to the healthcare industry. Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient client-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations. “The Innovative Technology contract from Vizient is a significant milestone for Cresilon and further validates the strong clinical feedback we have received since launching TRAUMAGEL last year,” said Joe Landolina, CEO and co-founder of Cresilon. “TRAUMAGEL is setting a new standard of care for hemorrhage control, and adoption is rapidly growing. This contract increases access to the technology for licensed medical professionals across the country to control bleeding in seconds and save lives.” TRAUMAGEL, which utilizes Cresilon’s proprietary hydrogel technology, is the first gel in a syringe for traumatic hemorrhage and the only flowable hemostatic with U.S. FDA 510(k) clearance for temporary external use to control moderate to severe bleeding. TRAUMAGEL is supplied in a 30 mL sterile prefilled syringe, requires no preparation, is easy to apply and remove, stops bleeding rapidly, and provides immediate hemorrhage control. “After a review of TRAUMAGEL, Vizient’s client-led council agreed this technology offers a unique benefit over other products available in the market today and recommended it for an Innovative Technology contract. We are pleased to award this new contract to Cresilon,” said Kelly Flaharty, associate vice president, contract operations for Vizient. Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $156 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with client-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle. Cresilon Receives Innovative Technology Contract from Vizient for TRAUMAGEL Contract awarded for products that bring improvement to healthcare industry consider all areas where employees demand or require support. Expanding the repertoire Health and wellbeing support has evolved a great deal in recent years. The support available can now be much more targeted. For instance, it can be targeted by issue, such as neurodiversity, and also by demographic, such as male-specific cancers, menopause, and fertility. It is important that all of these areas are considered, and some will be more important to some employees. Hence the need for wider benefits programmes that encompass specific and targeted support. Effective mental health support With so many employers planning to put time, effort and money into mental health, the support provided has to be effective. There also needs to be a return on investment in terms of the company benefiting as well as the employee. Fresh thinking and new ways of supporting employee mental health will be vital to making the change that has clearly been required for a number of years. Debra Clark says: “All areas of health and wellbeing have an impact on mental health, and the mental health of those around us can have an impact too. A full and rounded approach to supporting the whole health and wellbeing of all employees is likely to be the most effective option.”
GHP Q1 2026- Feature End-of-life care is clinically, ethically and operationally challenging because palliative and medical professionals work with symptom management, prognostic uncertainty and family involvement undertime constraints. Health information technology provides structure in those moments. When well done, it aligns documented preferences with bedside care, reducing ambiguity and supporting informed consent in routine and crisis settings. Advance Directives Integrated Into the Electronic Health Record (EHR) Health IT supports clinical practice and supplies the infrastructure for serious illness decision-making. The presence and use of health care AI are common. In an American Medical Association survey, 66% of physicians reported using health care AI in 2024. That degree of digital integration could suggest receptiveness to embedding advance care planning tools into clinical workflows. For advance directives to be effective, timely access to these documents is necessary, along with the capacity to act upon them. Entering code status, health care proxy and provider orders for lifesustaining treatment (POLST) information into structured fields in EHRs can reduce ambiguity during fast-paced transitions in care. By structuring documentation, clinical decision support can access preferences during order entry and care escalation. Interoperability — the ability to share and use health information across systems — may help resolve these problems. For example, advance directives shared across health information exchanges and available in the emergency department can help avoid duplication ofeffort and misaligned intentions. Financial Clarity for Complex Families Medical professionals face the challenges of blended families, estranged relatives and multiple candidate surrogates. Sixty-two percent of people under 55 have at least one stepkin relationship, which can muddy the waters about who’s in charge of health care and end-of-life decisions, as well as who is responsible for medical costs. Health IT systems that incorporate confirmation and conspicuous displays of the legally designated health care proxy may reduce conflict during emotionally intense moments. Trusts and other estate-planning tools can also provide added protection for blended families. Having a record with up-to-date fiduciary and health care proxy roles benefits the patients, family and the institute serving them. When scanned legal documents are available in the EHR and the proxy fields are coded, surrogate authority may be clearer. Shared Decision-Making (SDM) Tools at the Bedside SDM is an established process of combining clinical knowledge and patient values to ease informed consent. Its tools could display ranges of prognoses or the burdens and benefits of treatment in ways that preserve finer clinical subtleties. According to the Office of the National Coordinator for Health Information Technology’s latest report, 70% of non-federal acute care hospitals were able to send, receive, find and integrate electronic How Health IT Can Bring Clarity to End-ofLife Medical Decisions health information. Such interoperability provides the infrastructure for SDM modules to be integrated into clinical workflows and to follow patients across care settings. Effective platforms typically include: • Prognostic calculators: Evidence-basedalgorithms predicting survival or functional outcomes • Values clarification prompts: Questions about the relative importance of comfort, preservation ofcognition or longevity • Automated documentation templates: Discrete fields to record goals-of-care conversations For example, if clinicians enter evolving goals in structured formats, teams use them to interpret preferences regardless of clinical status. Communication Across Care Settings End-of-life care often spans multiple settings — including acute hospitals, skilled nursing facilities and home hospice — leading to reduced continuity of care and an increased risk of conflicting medical interventions. Since unnecessary medical tests and treatments cost billions of dollars a year, access to directives can prevent wasteful spending. Regular use of secure messaging, telehealth visits and standardization of discharge documents helps hospice providers avoid giving conflicting recommendations. Inpatient symptom management plans and code status documentation support integrated discharge summaries and reduce ambiguities during readmissions. Better data architecture can improve operations in serious illness care coordination. Ethical Guardrails Technology increases decision-making and risk. Advanced teams know that governance must be explicit. Consent management should be transparent, with audit logs that show who accessed advance directives and POLST forms. Role-based security protects sensitive information while ensuring appropriate clinical access. Providers should carefully evaluate embedded prognostic algorithms for data sources, validation cohorts and limitations and regularly assess for bias to ensure equitable decision support. The design of order-entry interfaces should prominently display code status and minimize alert fatigue. Visible preference systems help prevent clashes in care. Improved End-of-Life Medical Decisions Aided by Compassion Health IT can surface preferences, structure documentation and reduce conflict. It cannot experience fear, grief or hope. Balancing the integrity of evidence alongside humanity is a core skill all health care providers must develop. A positive and respectful balance is possible, which honors the clinical data alongside the dignity of the dying person. Leaders should ease and model systems that support this balance and provide the human empathy that technology cannot. Technological advances are driving the future of medicine, but computers can never replace human emotions and experience.
GHP Q1 2026 - Feature The drugs reaching the market in the coming years will increasingly be discovered, optimised, and validated by systems that many CEOs struggle to explain to their boards. Without governance frameworks that regulators can verify, innovation stalls. IDC forecasts that Global AI investment is expected to reach $632 billion by 2028, and Gartner predicts that by 2026, more than 80 per cent of businesses will have deployed generative AI-enabled applications in production environments, up from less than 5 per cent in 2023. But as the industry has learnt, velocity without security creates liability. As AI gains autonomy and regulatory frameworks tighten globally, the companies that secure their AI infrastructure will outpace those that defer. The leadership gap McKinsey’s 2025 analysis reveals the other side of the coin. Only 1% of CEOs believe their companies have mastered AI, yet roughly one in four companies are now assigning CEO-level oversight, with some extending it to the board. This signals accountability and AI security depends on that executive ownership. Leadership culture determines whether AI governance accelerates or constrains operations. Companies that treat security as a technical afterthought will struggle when regulatory scrutiny intensifies. Those who build it into decision-making from the start move faster. The same analysis reports that 13 per cent of companies overall have created dedicated AI governance or risk roles, signalling that this expertise is becoming as critical as expertise in drug development itself. The gap is not technical. Executives must balance innovation velocity with model transparency, data provenance and auditability across R&D, manufacturing and commercial operations. When AI systems are built with foundational governance, compliance accelerates the deployment process. Security and speed become interdependent. The regulatory convergence Regulatory agencies worldwide are tightening oversight around shared principles. Transparency, reproducibility and auditability are no longer aspirational; they are essential. In January 2025, the FDA issued draft guidance requiring post market monitoring, bias mitigation and transparency for AI-enabled medical devices. This applies to any AI system involved in diagnostics, patient care or clinical decision-making. The European Medicines Agency’s September 2024 Reflection Paper establishes that sponsors must “ensure that all algorithms, models, datasets and data processing pipelines used are fit for purpose and are in line with legal, ethical, technical, scientific and regulatory standards.” The paper warns that “new risks are introduced that need to be mitigated to ensure the safety of patients and integrity of clinical study results.” The MHRA How Leadership, Regulation and Trust Will Define AI’s Future in Pharma By Ramji Vasudevan of Altimetrik followed in April 2024 with a strategy prioritising safety, robustness, fairness and explainability. The ICH E6(R3) update, finalised in early 2025, codified these expectations globally, requiring full data integrity and audit trail documentation for clinical trials. These frameworks create both pressure and strategic advantage. Pharmaceutical companies that view compliance as a constraint will lag behind competitors who recognise security as the foundation for speed. Regulators are not demanding that AI innovation slows down. But they do require proof that systems function as intended, that results are reproducible and that decisions are traceable. This means demonstrating that an AI model recommending a compound for Phase II trials can explain its reasoning in terms a regulatory reviewer understands. It means proving that manufacturing parameter adjustments made by autonomous systems outside of working hours are auditable six months after the fact. Building this capability early means faster approvals, confident scaling and avoided remediation costs. Agentic risk and future resilience The next wave of operational risk emerges as AI systems gain autonomy. A September 2025 analysis emphasises that as agentic AI becomes embedded in critical workflows, companies must establish strong governance frameworks with clear accountability for decisions made by agents, guardrails to prevent unintended consequences and regular audits to ensure compliance. These systems do not wait for instructions to be given. They identify problems, propose solutions and execute tasks across interconnected operations. This autonomy accelerates drug discovery and clinical trial design but it also creates vulnerabilities that traditional security models cannot address. Leaders in the next decade are already building this infrastructure. When an agentic system excludes a patient cohort or flags a safety signal, regulators will demand explanations. Security becomes the foundation that enables autonomous intelligence to operate safely at scale. We have seen this first-hand through our own ALTi AI Adoption Lab, which provides pharmaceutical companies with secure environments to prototype and validate agentic systems before scale. Testing autonomous capabilities within frameworks designed for regulatory scrutiny from the outset proves that building systems that regulators can verify removes friction rather than adding it. AI governance does not have to be a bureaucratic overlay. It is the quality standard of digital pharmaceutical operations. The companies succeeding in 2030 will be those that recognised early that governance unlocks speed rather than constraining it. Leadership accountability is transforming governance into a competitive advantage as regulatory convergence establishes a global baseline. Innovation now depends on a capability boards often underestimate – explaining the intelligence that drives their pipeline.
8 GHP Q1 2026 In recent times, the need for a robust Clinical Supply Plan Strategy for clinical trials & clinical development programs has grown substantially. With a multitude of supply chain challenges, manufacturing delays, and product shortages, there’s never been a higher requirement for medical ancillary supplies & equipment & related services to reach clinical trial sites on time to maintain strict study timelines. We look at how, despite the challenges faced, Singapore-headquartered Intrinseque Health continues to provide best-in-class, global clinical supply chain services to its clients with efficiency and tact. As an EN ISO 13485, ISO 9001, ISO 27001 and GDPMDS certified global clinical trial support services provider, Intrinseque Health has become an expert in the art of delivering its incredible services to Drug Development organizations, Contract Research Organizations (CROs), and Pharmaceutical & Biotech companies throughout the industry. With a global reach, ability to source locally through its widespread & well-established network of manufacturers and strategic partners, Intrinseque Health has already proven itself as the goto clinical supply chain solutions provider for any challenges that conducting clinical trials may pose to its customers. Intrinseque Health recognizes the dynamics & challenges that each region, country, and market may present. These unique challenges can arise from several dynamics, such as ; regulatory requirements, logistics, product availability and related services. Intrinseque Health dedicates itself to overcoming these regulatory challenges and obstacles, all while ensuring that the required clinical supplies, equipment, and services are available whenever they are required at clinical trial sites, while doing so in a way that complies with critical regulatory guidelines to reduce or maintain study timelines. Not only is Intrinseque Health efficient, thanks to its operational methodology, it has been able to adapt and curate its services to be as efficient, effective & cost saving as possible. Intrinseque Health has also expanded its operational scope to include IMP Management & Non IMP Medicinal & Ancillary Supplies, Labelling and Kitting, Decentralized trials supply and Patient-care services. Intrinseque Health believes that the key to the success of a clinical supply plan is ‘Early Engagement’ and the strategies adopted to develop it. Intrinseque Health’s well established global sourcing & distribution network enables it to provide clinical supply chain services locally, eliminating possibilities of delays while maintaining critical study timelines. Intrinseque Health provides pressure-tested Clinical Supply Chain Strategies for each clinical trial through implementing customized strategies and solutions, while ensuring cost-effectiveness, and strives to ensure that all study supply requirements are fulfilled swiftly and carefully. This is achieved through the team’s 300 years of combined experience in supporting global clinical trials across a wide array of therapeutic areas. It values its customers above all and aims to provide the best services possible to its customers. Intrinseque Health engages with its customers on a profound level, and strives to truly understand them and their requirements, before tailoring supply plans specifically to their needs. Customer relationships serve as a backbone for Intrinseque Health’s services & operational methodology, and it understands that strong customer relationships play a crucial role in successful execution of planned clinical supply strategies. In addition to offering best in-class clinical supply chain solutions in the industry, Intrinseque Health continuously works towards a goal that it is already well on the way to accomplishing. With ambitions to become the leading global provider of clinical trial support services, Intrinseque Health assesses each step to reduce risks, navigate regulatory challenges, and present itself as the go-to clinical supply chain solutions provider that can truly be trusted and relied upon by its customers, while continuously adapting itself to the ever-changing landscape in the clinical trial sphere, so that it can provide the best service in the craft. With a long list of clients endorsing Intrinseque Health’s impressive service and capabilities, it becomes abundantly clear how Intrinseque Health has managed to consistently find itself earning award titles throughout the years. With industry service provisions & customercentric service that are unparalleled, and an undeniable dedication to its customers and their projects, Intrinseque Health truly is the clinical development supply chain solutions provider to rely on. No matter the request or timeframe, Intrinseque Health will devote itself wholeheartedly through its stringent Quality Management Systems and its robust and extensive operational methodology to ensuring that it plays its part diligently in ensuring the projects that it undertakes are an overwhelming success. Best Clinical Development Supply Chain Solutions Partner 2026
9 GHP Q1 2026 bbey House Dental comprises five state-of-the-art dental centres in Stone, Stoke-on-Trent and Rugeley Staffordshire. The aim across the locations is to provide patients in the area with dental care and treatment of the highest quality, making them feel at ease about going to the dentist and confident in showing off their smiles. This team here are all passionate about what they do, and it shows. Abbey House Dental makes a conscious effort to empower all team members, ensuring they have space to develop and that they feel valued. The positive attitudes fostered as a result translate into outstanding care for patients, which defines their journeys here. “We offer an exceptional patient journey, with our call centre team, reception term, patient coordinators, clinicians, and everyone in between all being there to provide a unique and tailored experience to every patient.” Staffordshire’s largest dental team, Abbey House Dental’s staff stand out due to the unrivalled expertise and exceptional dentistry this size brings about. For example, no external referrals are ever needed, as every patient can be treated fully in-house. Similarly, as the team behind the most Invisalign cases in the area, Abbey House Dental’s specialists are proud of their status as Diamond Apex Invisalign providers, putting them in the top one percent of service providers across the UK and Europe. When patients choose Abbey House Dental, the leading Invisalign dentist in Staffordshire, for Invisalign treatment, they get much more than just proper alignment, instead leaving with a new sense Invisalign treatment and dental implants are two of the primary reasons why people visit the dentist, and luckily for those based in the Stone, Stoke-on-Trent and Rugeley area, Abbey House Dental excels across them both – as well as all other aspects of family, aesthetic, cosmetic, and restorative dentistry. Named the Best Dental & Implant Care Practice 2026 – Staffordshire in this feature, we caught up Chloe Calitz for more on one of the region’s leading dental providers. Staffordshire’s Leading Invisalign and Implant Dentist of confidence and better oral hygiene (especially in cases of overcrowding). What’s more, the team also make use of Invisalign’s new AI features to give patients a realistic look at what their smile could look like after treatment. This is very powerful, with some patients even brought to tears by the experience. Of course, Invisalign is just one of Abbey House Dental’s specialties, with another being dental implants. Here, patients gain a tooth or an entirely new smile that looks and feels natural, with longevity guaranteed. Everything from discomfort when eating to hiding their face in public goes away after this treatment, as one patient’s testimonial outlines: “The end result was absolutely brilliant! it feels and looks like a real tooth, which has not only boosted my confidence but I can also eat what I like now.” Supporting this team as they deliver the gold standard of Invisalign and implant dentistry across Staffordshire is the latest technology, solidifying their status as ‘state of the art’. However, there is a healthy balance struck between the impersonality of technology and the warm smiles of the team, ensuring that even the most nervous patient can relax in an environment that does not feel cold and clinical. This undoubtedly contributes to Abbey House Dental’s 2000+ five-star Google reviews. Beyond its impeccable dentistry, another thing that patients at Abbey House Dental love is its commitment to giving back to the community. The best example of this is its second annual charity ball, scheduled for September. The last edition of the event, held near its centre in Festival Park, Stoke-on-Trent, saw more than £15k raised and split between three charities, one of which was Gracie May’s Dream a Little Dream, established by a team member who sadly lost her four-year-old daughter to liver cancer. With tickets for this event set to go on sale soon, and the team currently in the process of renovating a new practice they took over last August, the rest of 2026 is set to be a busy yet exciting time for Abbey House Dental, which otherwise remains dedicated to preserving its status as the best dentist for implants and Invisalign in Staffordshire. Those looking to learn more about Abbey House Dental can do so in several ways, including the weekly podcast it runs, discussing dentistry and breaking things down. Abbey House Dental – The Podcast can be accessed via YouTube, Spotify, and Apple. Its website is below, where links to all of its social media pages can also be found. Contact: Chloe Calitz Company: Abbey House Dental Web Address: https://abbeyhousedental.com/ A
10 Characterised by high pressure and even higher stakes, clinical trials are environments in which business success is overshadowed only by the prospect of advancing the state of human health. These lifechanging studies must be kept moving forward, delivered through systems designed to drive confident decisions and calm action. Global technology firm Suvoda has stepped up to the plate in an increasingly complex industry, delivering a market-leading software platform equipped to support the most critical moments in a trial. We heard more from Robin Abadía below, Director of External Communications at Suvoda, as the company is named in the Global Excellence Awards 2026. For over a decade, Suvoda has been on a mission to advance human health by streamlining the clinical trial experience for patients, sites, sponsors, and CROs alike. To do so, it has developed a patented, realtime software platform that is purpose-built for the most complex, mission-critical, and time-sensitive moments in studies. This platform empowers sponsors and sites to make confident decisions and take calm action whilst operating within high-stakes studies. Suvoda was founded in 2013 by CEO Jagath Wanninayake, COO Robert Hummel, and other experts who were driven by a desire to ease the complexities faced by clinical trial participants and professionals. Jagath’s background in clinical trial technology, which also includes previous experience as the Co-Founder of Clarix LLC, has laid the foundation for Suvoda’s innovative approach to clinical trials and has since propelled the team to significant success. The pioneering Suvoda Platform provides a suite of eight products on a single, patented ecosystem: IRT, eCOA, eConsent, Greephire Patient Payments, Greenphire Travel, Scheduling, Site Payments, and Budgeting and Benchmarking. This fully integrated model minimises friction and maximises engagement for sponsors, CROs, sites, and patients, not only simplifying but enhancing the experience and contributions of all users across the clinical journey. “We support even the most time-sensitive, mission-critical points of a trial, so that life-changing studies keep moving forward and everyone involved can ‘trial wisely’.” “You’ll hear the term ‘platform’ used in many ways in our industry,” said Robin. “At Suvoda, it reflects a unified architecture built intentionally as a single system. Rather than integrating standalone products, our patented, modern back-end supports connected workflows and a streamlined user experience across the trial lifecycle.” Using the Suvoda Platform, study teams benefit from a single log-in, a unified data layer, and an intuitive interface that was created with user-centricity in mind. Beyond the technology itself, the company’s exceptionally prepared client services teams support sponsors and CROs for the full lifespan of each trial, providing protocol-level expertise, calm guidance, and global support. Since its launch, Suvoda has been chosen to support sponsors and CROs in more than 2,000 trials across over 95 countries, including many of the most complex and high-stakes studies in oncology and rare disease. Meticulously monitoring customer satisfaction and feedback, the company consistently achieves scores that exceed typical technology industry benchmarks, reflecting the trust that clients have placed in its platform and services. External validation, from industry awards and analyst reports to strategic partnerships and growing adoption, have further evidenced that Suvoda is meaningfully enhancing the clinical trial journey. “We pride ourselves on being deeply patient- and site-centric, designing digital experiences that not only streamline trial operations but also reduce friction for the people actually moving through trials,” Robin told us. “People now expect, and deserve, Suvoda: Pioneering For Patients, For Professionals, For Progress “Together, we Trial wisely.”
GHP Q1 2026 to have technology that just works. That’s especially needed for the high-stakes world of clinical trials. We’re proud to be seen as an innovator and leader in our space, with five U.S. patents for our platform architecture and independent recognition from analysts for our impact on clinical trial technology.” Building on its exceptional success, Suvoda has developed a groundbreaking patient app. The Suvoda patient app provides trial participants with a single, intuitive mobile experience that allows them to manage the essentials of their trial needs in one unified place. On their own device, users can receive visit reminders and view upcoming visit schedules, complete eCOA questionnaires and fill out daily diaries, arrange travel details, and track patient payments and reimbursements, all without the unnecessary burden of juggling emails, calls, and papers. The bright minds at Suvoda created Sofia, an AI assistant. Currently available on Suvoda IRT, the company’s software for patient randomisation and trial drug supply management, with plans to extend across the Suvoda Platform. Sofia transforms what used to be multi-screen, multi-click workflows into simple, auditable conversations. With Sofia, Suvoda aims to help study teams quickly access trial data, reports, and documentation through a secure, streamlined chat interface. Together, these innovations enable Suvoda to further unify the digital experience for patients while simplifying day-to-day work for sites and sponsors. With all features comprised in a sole, user-friendly interface, the patient app promises higher patient engagement, fewer missed visits, and better participant retention. With many administrative tasks now streamlined into a guided, self-service experience for patients, site burden is reduced as staff are free to shift their focus from coordination to clinical care. Furthermore, study teams can make faster and more confident decisions with support from Sofia. Without compromising role-based access or blinding, the AI technology can surface information such as inventory levels, shipment, or visit data; create tables and charts; and link directly to relevant sections of user manuals. Powered by the same unified Suvoda Platform, these innovations make for a more connected ecosystem overall, allowing data and workflows to move smoothly between patient, site, and sponsor tools. Of course, as with many industries, one of the biggest developments on everyone’s mind is the use of AI. The technology has significant potential, but there is absolutely no room for error in the field of clinical trials, when dealing with patient’s health or the carefully designed protocols of a clinical trial study. With this understanding, Suvoda’s approach to AI is innovation with guardrails: every AI use case must be reliable, secure, and fully auditable. This can be seen most clearly in Sofia. The AI agent is designed to only answer questions it has been taught to answer using expert-authored instructions, has been validated by humans, and operates within strict role-based access that maintains study blind. What’s more, with “zero-day” data retention, Sofia never exposes data beyond a user’s permissions and never uses customer data to train public models. “AI brings both opportunities and challenges to our industry,” Robin stated. “Sponsors and sites want faster, simpler ways to work, but they’re rightly cautious about AI risk. We’ve turned that tension into an advantage by harnessing AI in ways that support our users while also preserving the precision that our industry demands.” In the coming years, Suvoda will continue to combine innovation with expertise so that it can support end users whilst responding directly to the needs of the industry. In alignment with this mission, the company is excited to deliver on its promise of the Suvoda-Greenphire merger announced last year. By uniting its core systems for trials, comprising randomisation, drug supply, consent, and eCOA – with Greenphire’s strength in patient payments, patient travel, budgeting, and site payments, Suvoda is making significant strides in building a truly endto-end platform that serves the needs of clinical trial sponsors. Through 2026 and beyond, Suvoda seeks to help sponsors move away from fragmented point solutions and transition to its unified suite of solutions. The benefits are myriad: patients and sites can experience a single, intuitive platform and Suvoda app that handles their needs; sites deal with fewer systems and less manual reconciliation so they can focus on care; while sponsors and CROs gain a trusted partner providing connected clinical and financial data, allowing them to see what is happening across enrolment, logistics, and budgets, and act faster. Ultimately, Suvoda’s unified tech suite opens up workflow improvements that the healthcare sector has been long overdue. Through its pioneering platform, patient-preferred app, and complementing AI assistant, the company has successfully developed a comprehensive ecosystem that streamlines the clinical trial process for all involved. With plans for further innovation already underway, Suvoda is gearing up for another year of making meaningful impact on the state of human healthcare, a mission that has earned it recognition as the Most Innovative Clinical Trial Technology Firm 2026. Company: Suvoda Web Address: www.suvoda.com
12 GHP Q1 2026 hrough her clinic, Dr Raquel Skin & Medical Cosmetics, Dr Raquel helps her patients with their natural confidence, providing advanced aesthetic, skin, hair, and general wellness treatments so they look and feel like the best versions of themselves. A big part of this is ensuring treatments offer natural-looking outcomes, so that patients do not appear ‘overdone’. To make sure that all of the men and women the clinic sees are afforded this, Dr Raquel and her team work ethically and professionally, tailoring all their treatments. Looking more closely at this, Dr Raquel told us: “We assess the face holistically to restore balance, structure, and skin quality in a subtle, natural way, through treatments all tailored to the individual following an in-depth consultation.” Nowhere is this more apparent than through the clinic’s Signature Specials, available for new and existing patients alike. These fully customisable, 360-degree plans have been designed to offer a holistic approach spanning skin, volume loss, and overall health, making them unique in this space. For example, new patients can enjoy Dr Racquel’s Radiance Lift – which offers lifted skin in just one appointment via a cuttingedge treatment blending dermal fillers and toxin – or Dr Raquel’s RegenLift Series, where, over four monthly appointments, the team chip away at a multi-faceted plan addressing every element of ageing skin. A journey to the youthful radiance patients seek, these treatments bring together some of the most desirable services from across this portfolio, yet still barely scratches the surface of the full range available. “We also specialise in advanced skin and hair restoration treatments, helping patients address concerns such as pigmentation, acne scarring, premature ageing, and hair thinning through our clinically proven, evidencebased solutions.” T Dr Raquel Amado’s name precedes her in the world of doctor-led aesthetics, with this LMD/dental surgeon graduating as a dentist nearly 20 years ago in Portugal, before becoming a qualified aesthetic practitioner, renowned senior clinic trainer,facultymember,andinternational speaker for various institutions. Her medical aesthetics clinic in Kent is a testament to her expertise, and on the back of its recognition as the Best Skin, Hair & Wellness Clinic – Southeast, we caught up with Dr Raquel herself. All of the high-quality treatments delivered by Dr Raquel and her team across the areas of face, skin, hair, and wellness benefit from the clinic’s discreet and friendly atmosphere. So, whether a patient is searching for polynucleotides for their skin, support with their excessive underarm sweating, help managing their acne, menopause assistance, or anything else from across the clinic’s natural, injectable treatments, Dr Raquel and co. are passionate about seeing that everyone who enters the clinic achieves their aesthetic goals quickly and safely. Supporting Raquel in the delivery of these treatments is Elizabeth Caroline, also known as the ‘Skin Samurai’. Elizabeth has more than 20 years of experience in the skin and wellness industry, beginning as a massage and sports therapist before pivoting to become a successful facialist operating out of both Mayfair and Harley Street in London. However, more than her experience, what sets Elizabeth apart is her deeply spiritual nature, nurtured by her training under a Buddhist monk, which resulted in this nickname and an influx of patients. The Skin Samurai’s patient portfolio is incredibly impressive as a result, with big names in celebrity and influencer circles – Ellie Goulding, Nicola Roberts, and Mille Mackintosh, to name just a few – having worked with her. Sadie Frost even credited Elizabeth with delivering one of the best facials in the world, and publications such as Glamour UK, Hello!, and Harper’s Bazaar have all featured her treatments. Such an impressive portfolio makes Elizabeth the perfect person to complement Dr Raquel at the clinic. Rounding out the team here is Natalie Parchment, whose role as the coordinator of the clinic sees her deliver the personalised service Dr Raquel Skin & Medical Cosmetics is known for from the moment a patient’s journey begins. Natalie’s welcoming presence comes from a background in high-end customer service, and as the first face clients see when they enter the clinic and the last face they see before they leave, Natalie’s importance in bookending this experience cannot be overstated, and Dr Raquel values her greatly. Combined, what Dr Raquel Amado and the team at Dr Raquel Skin & Medical Cosmetics deliver is an experience like no other, as seen through the number of awards they have been presented with over the years, including in a previous edition of this feature. For continuing to set the standard for doctor-led medical aesthetic clinics in Kent and beyond, it is our pleasure to again recognise this clinic, this time as the Best Skin, Hair & Wellness Clinic – Southeast. More on its regenerative aesthetic treatments can be found below. Contact: Dr Raquel Amado Company: Dr Raquel Skin and Medical Cosmetics Web Address: https://skinandmedicalcosmetics.co.uk/ PersonalisedTreatments at Kent’s Doctor-Led Aesthetics Clinic
13 GHP Q1 2026 skincare education, sun protection, and long-term skin health,” Dr M.Sha explained. “Patients can be vulnerable, and we believe it is our responsibility to protect them, not take advantage of them.” This approach is especially important in today’s aesthetics landscape. At present, there is significant concern surrounding the ongoing lack of regulation, which has led to serious complications even fatalities linked to unsafe practices. These unfortunate events highlight the crucial need for medical oversight and proper training across the industry. At the same time, patients are experiencing rising economic pressures, which calls the affordability of treatments into question. Dr M.Sha addresses such challenges by providing honest advice, realistic planning, and prioritising the education of its patients. In doing so, the clinic avoids pushing unnecessary treatments and further contributes to the industry’s demand for responsible practices. Looking to the future, Dr M.Sha intends to continue setting the benchmark of excellence across the wellness and aesthetics industry, with plans that reflect her steadfast dedication to education and clinical excellence. “Over the next five years, my goal is to grow and eventually own a larger clinic with a strong multidisciplinary team,” she told us. “I also aim to further develop my role as an educator within the aesthetics industry. I am currently an ambassador for Mesoestetic and in discussion for a Key Opinion Leader role with Neauvia.” Dr M.Sha Wellness and Aesthetics Clinic will also see a whole host of upcoming projects coming to fruition. In addition to progressing Dr M.Sha’s KOL role with Neauvia, the clinic looks to expand its regenerative and wellness, while also continuing efforts to raise awareness about intimate health rejuvenation for women, particularly within the postnatal and menopausal population. These endeavours will allow Dr M.Sha Wellness and Aesthetics Clinic to make significant strides towards industry-wide excellence, while also reaffirming its position as Stoke’s Best Wellness and Aesthetics Clinic 2026. Contact: Dr Muqaddas Shafiq Company: Dr M.Sha Wellness and Aesthetics Clinic Web Address: www.drmshaclinic.com Standing as Staffordshire’s trusted source for cutting-edge technology and personalised care, Dr M.Sha Wellness and Aesthetics Clinic is a leading clinic dedicated to subtle, natural-looking results. The clinic is led by Dr M. Sha (MBChB, MRCGP UK) , a highly qualified medical practitioner boasting more than 12 years of experience within the field. Leveraging this invaluable expertise, she leads her team with an approach that combines evidence-based treatments with honest, personalised advice. While Dr M. Sha oversees all clinical care as a General Practitioner and Aesthetic Doctor, husband Dr Hasan Uppal (PhD) is a research scientist in nanoelectronics and supports the clinic by evaluating the science, technology, and safety behind every product and device it introduces. This multidisciplinary, husband-and-wife collaboration allows Dr M.Sha Wellness and Aesthetics Clinic to offer treatments that are effective but also properly researched, safe, and results-driven. “Our mission is to deliver safe, ethical, and medically led aesthetic care that focuses on long-term health, not quick fixes,” Dr M. Sha informed us. “We believe in honest consultations, evidence-based treatments, and doing what is genuinely right for each patient. Our core values are safety. Integrity, education, and personalised care, and we never compromise these for trends or sales.” “We believe in honest consultations, evidence-based treatments, and doing what is genuinely right for each patient.” In a competitive market, Dr M.Sha Wellness and Aesthetics Clinic stands out for specialising in regenerative treatments that focus on wellness from within. This includes Neogen plasma, polynucleotides, microneedling radiofrequency, and exosome-based therapies. These treatments aim to improve skin quality, repair, and function, rather than simply masking ageing. Alongside this, Dr M.Sha Wellness and Aesthetics Clinic provides minor surgical procedures, such as mole and skin tag removal for patients who are unable to access these services through the NHS. It has also launched intimate health rejuvenation treatments for vaginal laxity and stress incontinence, particularly supporting women after childbirth and during menopause. Across its treatments, Dr M.Sha upholds an unwavering commitment to medical oversight, ethical practice, and patient education. “We often say no to treatments when they are not needed, and prioritise The aesthetics industry is a complex environment, requiring a specialised approach and exceptional standards. Unfortunately, the industry is also highly saturated with unregulated entities, forcing patients to be discerning when accessing treatment. Dr M.Sha Wellness and Aesthetics Clinic shines in this respect, especially as a Save Face registered clinic with a stringent focus on utilising its medical and scientific expertise to provide treatments that are research- and results-driven. We spoke with Medical Director Dr M.Sha below, as the clinic receives recognition in the Global Excellence Awards 2026. Regenerative Treatments with Results You Can Trust
ghpnews.digitalRkJQdWJsaXNoZXIy NTY1MjM3